Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib versus methotrexate in early seropositive rheumatoid arthritis with assessment of joint and lung disease activity
2019-004179-38Phase 4Terminated
- Sponsor
- Region Västra Götaland
- Start
- Nov 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of tofacitinib and methotrexate in rheumatoid arthritis (RA) (2 arms), sponsored by Region Västra Götaland. Primary endpoint: Change in total interstitial pulmonary abnormality score at 24 weeks. Started Nov 2019; status: terminated.
02
Drugs
tofacitinibmethotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2019-004179-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004179-38.